Department of Gastrointestinal Oncology.
Department of Gastrointestinal Oncology.
Gastrointest Endosc. 2023 Aug;98(2):170-177. doi: 10.1016/j.gie.2023.03.017. Epub 2023 Mar 27.
Local triamcinolone (TA) injection is widely used to prevent stricture formation after endoscopic submucosal dissection (ESD). However, stricture develops in up to 45% of patients despite this prophylactic measure. We therefore conducted a single-center prospective study to identify predictors of stricture after esophageal ESD and local TA injection.
Patients who underwent esophageal ESD and local TA injection and who were comprehensively assessed for lesion- and ESD-related factors were included in the study. Multivariate analyses were conducted to identify the predictors of stricture.
A total of 203 patients were included in the analysis. Multivariate analysis identified residual mucosal width ≤5 mm (odds ratio [OR], 29.0; P < .0001) or 6 to 10 mm (OR, 3.7; P = .04), history of chemoradiotherapy (OR, 5.1; P = .045), and tumor in the cervical or upper thoracic esophagus (OR, 3.8; P = .018) as independent predictors of stricture. Based on the ORs of the predictors, patients were stratified into 2 groups according to stricture risk: patients in the high-risk group (residual mucosal width ≤5 mm or 6-10 mm with another predictor) had a stricture rate of 52.5% (31 of 59 cases), and patients in the low-risk group (residual mucosal width ≥11 mm or 6-10 mm without other predictors) had a stricture rate of 6.3% (9 of 144 cases).
We identified predictors of stricture after ESD and local TA injection. Local TA injection prevented stricture formation after ESD in low-risk patients but was not sufficient to prevent stricture in high-risk patients. Additional interventions should thus be considered in high-risk patients. (University Hospital Medical Network Clinical Trials Registry number: UMIN 000028894.).
局部曲安奈德(TA)注射广泛用于预防内镜黏膜下剥离术(ESD)后狭窄的形成。然而,尽管采取了这种预防措施,仍有多达 45%的患者发生狭窄。因此,我们进行了一项单中心前瞻性研究,以确定食管 ESD 及局部 TA 注射后狭窄的预测因素。
纳入了接受食管 ESD 和局部 TA 注射且全面评估了病变和 ESD 相关因素的患者。进行了多变量分析以确定狭窄的预测因素。
共纳入 203 例患者进行分析。多变量分析发现,残留黏膜宽度≤5mm(比值比[OR],29.0;P<0.0001)或 6 至 10mm(OR,3.7;P=0.04)、放化疗史(OR,5.1;P=0.045)和颈段或胸上段食管肿瘤(OR,3.8;P=0.018)是狭窄的独立预测因素。根据预测因素的 OR,根据狭窄风险将患者分为 2 组:高危组(残留黏膜宽度≤5mm 或 6-10mm 且存在另一个预测因素)狭窄发生率为 52.5%(59 例中的 31 例),低危组(残留黏膜宽度≥11mm 或 6-10mm 且无其他预测因素)狭窄发生率为 6.3%(144 例中的 9 例)。
我们确定了 ESD 和局部 TA 注射后狭窄的预测因素。局部 TA 注射可预防 ESD 后低危患者发生狭窄,但不足以预防高危患者发生狭窄。因此,高危患者应考虑额外干预。(大学医院医疗网络临床试验注册编号:UMIN 000028894。)